Pioglitazone is an approved anti-hyperglycemic medication and is thought to have anti-inflammatory properties. This study seeks to gather safety and tolerability data related to pioglitazone when given to patients who require hospital admission for confirmed positive COVID-19 infections with elevated blood sugar levels as compared to patients who did not receive pioglitazone during their hospitalization for COVID-19.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
10
Receive pioglitazone 15mg - 30mg daily
Good Samaritan Hospital Corvallis
Corvallis, Oregon, United States
Adverse events outcomes without attribution
Number and type of adverse events
Time frame: Baseline, until 30 days after last dose
Adverse events attributable
Number and type of adverse events
Time frame: Baseline, until 30 days after last dose
Clinical improvement
Disease severity as measured by 7 point ordinal scale
Time frame: Baseline, until 30 days after last dose
Levels of treatment
Type of oxygen support treatment
Time frame: Baseline, until 30 days after last dose
d-Dimer
Change from Baseline of d-Dimer
Time frame: Baseline, until 30 days after last dose
C Reactive Protein
Change from Baseline of CRP
Time frame: Baseline, until 30 days after last dose
Ferritin
Change from Baseline of Ferritin
Time frame: Baseline, until 30 days after last dose
Lactate dehydrogenase
Change from Baseline of Lactate dehydrogenase
Time frame: Baseline, until 30 days after last dose
A1c
Change from Baseline of A1c
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Baseline, until 30 days after last dose